Tenax Therapeutics (TENX) shareholders elect full board, ratify 2026 auditor
Rhea-AI Filing Summary
Tenax Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders held on June 2, 2026. Stockholders elected seven directors, including June Almenoff, Michael Davidson, Declan Doogan, Christopher T. Giordano, Robyn M. Hunter, Gerald T. Proehl, and Stuart Rich, each to serve a one-year term expiring in 2027.
Each director nominee received between 15,762,162 and 17,397,413 votes in favor, with additional withheld votes and 3,742,678 broker non-votes recorded for each. Stockholders also ratified the appointment of Cherry Bekaert LLP as the company’s independent registered public accounting firm for the year ending December 31, 2026, with 21,304,543 votes for, 3,688 against, and 11,073 abstentions.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Votes for June Almenoff: 17,362,177 votes
Votes for Michael Davidson: 15,762,162 votes
Broker non-votes on director elections: 3,742,678 shares
+3 more
6 metrics
Votes for June Almenoff
17,362,177 votes
Director election at 2026 annual meeting
Votes for Michael Davidson
15,762,162 votes
Director election at 2026 annual meeting
Broker non-votes on director elections
3,742,678 shares
Each director election, June 2, 2026 meeting
Auditor ratification for-votes
21,304,543 votes
Ratification of Cherry Bekaert LLP for 2026
Auditor ratification against-votes
3,688 votes
Ratification of Cherry Bekaert LLP for 2026
Auditor ratification abstentions
11,073 votes
Ratification of Cherry Bekaert LLP for 2026
Key Terms
annual meeting of stockholders, broker non-votes, independent registered public accounting firm, emerging growth company
4 terms
annual meeting of stockholders regulatory
"On June 2, 2026, Tenax Therapeutics, Inc. held its 2026 annual meeting of stockholders"
broker non-votes financial
"by the votes indicated below ... Broker Non-Votes 3,742,678"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm regulatory
"ratified the appointment of Cherry Bekaert LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Tenax Therapeutics (TENX) stockholders decide at the 2026 annual meeting?
Stockholders elected seven directors to one-year terms and ratified the independent auditor. The board slate, including CEO Christopher T. Giordano, was approved, and Cherry Bekaert LLP was confirmed to audit the company for the year ending December 31, 2026.
Who was elected to the Tenax Therapeutics (TENX) board in 2026 and for how long?
Seven directors were elected for one-year terms expiring in 2027. The directors are June Almenoff, Michael Davidson, Declan Doogan, Christopher T. Giordano, Robyn M. Hunter, Gerald T. Proehl, and Stuart Rich, each serving until 2027 or until a successor is duly elected.
How did Tenax Therapeutics (TENX) stockholders vote on auditor ratification for 2026?
Stockholders ratified Cherry Bekaert LLP as independent registered public accounting firm. The vote totals were 21,304,543 shares for, 3,688 against, and 11,073 abstaining, with no broker non-votes reported for this proposal in the results disclosed.
When was the Tenax Therapeutics (TENX) 2026 annual meeting of stockholders held?
The 2026 annual meeting of stockholders was held on June 2, 2026. At this meeting, shareholders voted on the election of seven directors and on the ratification of Cherry Bekaert LLP as the independent registered public accounting firm for the 2026 fiscal year.
What are broker non-votes in the Tenax Therapeutics (TENX) 2026 meeting results?
Broker non-votes represent shares held by brokers that did not receive voting instructions from beneficial owners on non-routine matters. For each director election proposal, 3,742,678 broker non-votes were recorded, meaning those shares were not counted as for or against those nominees.
Did any Tenax Therapeutics (TENX) director nominee fail to receive majority support in 2026?
All seven director nominees received strong support from voting stockholders. Each nominee, including Michael Davidson who had the lowest for-vote total, received at least 15,762,162 votes for, exceeding the withheld votes reported for that nominee in the disclosed results.